Introduction: Brachytherapy may be complicated by serious obstructive voiding symptoms (OVS). Only conservative treatment options are available in the first 6 months after brachytherapy. We evaluated safety, efficacy and patient tolerance of the Memokath prostatic stent (MPS). Material and Methods: A MPS was placed in 10 patients with OVS after brachytherapy. Evaluation included uroflowmetry, international prostate symptom score (IPSS), prostate volume and urethrocystoscopy before and 3 months after placement of the stent. Results: Both the IPSS and uroflowmetry results significantly improved after stent insertion. The mean IPSS decreased from 29/5 to 11/1 and the mean Qmax from the uroflowmetry improved from 4.7 to 11.2 ml/s. The 5 patients who were catheter dependent voided spontaneously with a mean Qmax of 15 ml/s. Two stents migrated towards the bladder, and those patients needed a second stent which was placed without complications. Removal of the stent was easy to perform. Adverse effects were minor with perineal pain and irritative voiding symptoms occurring in 5 patients mainly in the first weeks after insertion. This did not negatively influence quality of life and all patients were more satisfied with the stent than without. Conclusions: The MPS provides a safe, effective, and completely reversible treatment for patients with OVS after brachytherapy and was well tolerated.

Keywords:
Brachytherapy, Obstructive voiding symptoms, Prostate, Prostatic outflow obstruction, Quality of life, Stent, Urinary retention
1.
Cooperberg MR, Moul JW, Carroll PR: The changing face of prostate cancer. J Clin Oncol 2005;23:8146-8151.
2.
Stone NN, Stock RG: Complications following permanent prostate brachytherapy. Eur Urol 2002;41:427-433.
3.
Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ: Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 2005;63:772-780.
4.
Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM: Factors predicting for urinary morbidity following 125-iodine transperineal prostate brachytherapy. Radiother Oncol 2004;73:33-38.
5.
Wehle MJ, Lisson SW, Buskirk SJ, Broderick GA, Young PR, Igel TC: Prediction genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc 2004;79:314-317.
6.
Keyes M, Schellenberg D, Moravan V, McKenzie M, Agranovich A, Pickles T, Wu J, Liu M, Bucci J, Morris WJ: Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 2006;64:825-834.
7.
Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M: Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
8.
Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E: The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 64:136-143.
9.
Mallick S, Azzouzi R, Cormier L, Peiffert D, Mangin PH: Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2003; 92:555-558.
10.
Sherertz T, Wallner K, Wang H, Sutlief S, Russell K: Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 2001;51:1241-1245.
11.
Fabian KM: The intra-prostatic ‘partial catheter' (urological spiral). Urologe A 1980;19:236-238.
12.
Perry MJ, Roodhouse AJ, Gidlow AB, Spicer TG, Ellis BW: Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int 2002:90:216-223.
13.
Oesterling JE, Kaplan SA, Epstein HB, Defalco AJ, Reddy PK, Chancellor MB: The North American experience with the UroLume endoprothesis as a treatment for benign prostatic hyperplasia: long term results. The North American UroLume Study Group. Urology 1994:44:353-362.
14.
Badlani GH, Press SM, Defalco A, Oesterling JE, Smith AD: UroLume endourethral prosthesis for the treatment of urethral stricture disease: long term results of the North American Multicenter UroLume Trial. Urology 1995:45:846-656.
15.
Juma S, Niku SD, Brodak PP, Joseph AC: Urolume urethral wallstent in the treatment of detrusor sphincter dyssynergia. Paraplegia 1994:32:616-621.
16.
Armitage JN, Cathcart PJ, Rashidian A, De Nigris E, Emberton M, van der Meulen JH: Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 2007;177:1619-1624.
17.
Bajoria S, Agarwal SA, White R, Zafar F, Williams G: Experience with the second generation UroLume prostatic stent. Br J Urol 1995:75:325-327.
18.
Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH: The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 2004;94:1271-1274.
19.
Armitage JN, Rashidian A, Cathcart PJ, Emberton M, van der Meulen JH: The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int 2006:98:806-810.
20.
Porru D, Jallous H, Cavalli V, Sallusto F, Rovereto B: Prognostic value of a combination of IPSS, flow rate and residual urine volume compared to pressure-flow studies in the preoperative evaluation of symptomatic BPH. Eur Urol 2002;41:246-249.
21.
Meijer GJ, van den Berg HA, Hurkmans CW, Stijns PE, Weterings JH: Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy. Radiother Oncol 2006;80:378-384.
22.
Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): The 2nd International Consultation on Benign Prostatic Hyperplasia. Channel Island, Scientific Communication International Ltd, 1994, pp624-631.
23.
Merrick GS, Butler WM, Wallner KE, Galbreath RW: Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;58:81-88.
24.
Kollmeier MA, Stock RG, Cesaretti J, Stone NN: Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005;173:808-812.
25.
Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV, Zincke H, Blute ML: Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol 2005;173:1953-1957.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.